Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion type Assertion NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_head.
- NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion description "[As part of a phase I clinical trial to document the safety and efficacy of intramuscular gene transfer of naked plasmid DNA-encoding vascular endothelial growth factor (phVEGF165) in the treatment of critical limb ischemia, we treated TAO in 6 patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_provenance.
- NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion evidence source_evidence_literature NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_provenance.
- NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion SIO_000772 9845647 NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_provenance.
- NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion wasDerivedFrom befree-20140225 NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_provenance.
- NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_assertion wasGeneratedBy ECO_0000203 NP238639.RAVOFqNdRZGwrzcC6YaqGSt9rZRvvoQQcNMennAJVP2q4130_provenance.